Gena Wang
Stock Analyst at Barclays
(3.19)
# 1,131
Out of 5,136 analysts
239
Total ratings
44.87%
Success rate
2.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Overweight | $82 → $87 | $63.33 | +37.38% | 5 | Dec 22, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $81 → $50 | $24.11 | +107.38% | 7 | Nov 24, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $94 → $90 | $22.57 | +298.76% | 7 | Nov 13, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $38 → $33 | $7.86 | +319.85% | 3 | Nov 11, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $31 → $25 | $39.60 | -36.87% | 11 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $24 → $14 | $11.74 | +19.25% | 9 | Nov 7, 2025 | |
| SGMO Sangamo Therapeutics | Downgrades: Equal-Weight | $5 → $1 | $0.45 | +123.02% | 5 | Nov 7, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $46 → $68 | $75.40 | -9.81% | 17 | Nov 6, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Equal-Weight | $22 → $20 | $21.46 | -6.80% | 16 | Nov 5, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $408 → $414 | $454.67 | -8.94% | 18 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $9 | $5.16 | +74.42% | 8 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $6.75 | +33.33% | 11 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $527 | $369.96 | +42.45% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $95 | $79.48 | +19.53% | 14 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $80 | $55.20 | +44.93% | 16 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $4.25 | +88.24% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $7 → $17 | $28.32 | -39.97% | 10 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $37 | $15.05 | +145.85% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $59 → $62 | $72.43 | -14.40% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $56 | $56.18 | -0.32% | 17 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $21 | $34.55 | -39.22% | 10 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $6.31 | +391.28% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $2.09 | +43.54% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $23.92 | -62.37% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $7.57 | +230.25% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $7.38 | +143.90% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $6.24 | +44.23% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.09 | +5,302.75% | 1 | Jan 6, 2017 |
Cytokinetics
Dec 22, 2025
Maintains: Overweight
Price Target: $82 → $87
Current: $63.33
Upside: +37.38%
Ultragenyx Pharmaceutical
Nov 24, 2025
Maintains: Overweight
Price Target: $81 → $50
Current: $24.11
Upside: +107.38%
Legend Biotech
Nov 13, 2025
Maintains: Overweight
Price Target: $94 → $90
Current: $22.57
Upside: +298.76%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Overweight
Price Target: $38 → $33
Current: $7.86
Upside: +319.85%
Moderna
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $39.60
Upside: -36.87%
Intellia Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $24 → $14
Current: $11.74
Upside: +19.25%
Sangamo Therapeutics
Nov 7, 2025
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $0.45
Upside: +123.02%
PTC Therapeutics
Nov 6, 2025
Maintains: Equal-Weight
Price Target: $46 → $68
Current: $75.40
Upside: -9.81%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $22 → $20
Current: $21.46
Upside: -6.80%
Vertex Pharmaceuticals
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $408 → $414
Current: $454.67
Upside: -8.94%
Nov 4, 2025
Maintains: Overweight
Price Target: $10 → $9
Current: $5.16
Upside: +74.42%
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $6.75
Upside: +33.33%
Oct 31, 2025
Maintains: Overweight
Price Target: $460 → $527
Current: $369.96
Upside: +42.45%
Oct 30, 2025
Maintains: Overweight
Price Target: $80 → $95
Current: $79.48
Upside: +19.53%
Oct 28, 2025
Maintains: Overweight
Price Target: $86 → $80
Current: $55.20
Upside: +44.93%
Oct 17, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $4.25
Upside: +88.24%
Sep 25, 2025
Upgrades: Equal-Weight
Price Target: $7 → $17
Current: $28.32
Upside: -39.97%
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $15.05
Upside: +145.85%
Aug 8, 2025
Maintains: Overweight
Price Target: $59 → $62
Current: $72.43
Upside: -14.40%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $56.18
Upside: -0.32%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $34.55
Upside: -39.22%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $6.31
Upside: +391.28%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $2.09
Upside: +43.54%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $23.92
Upside: -62.37%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $7.57
Upside: +230.25%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $7.38
Upside: +143.90%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $6.24
Upside: +44.23%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.09
Upside: +5,302.75%